Oncotype DX Genomic Prostate Score

Interpreting GPS Results

Predict both clinical risk and tumor aggressiveness

Oncotype DX GPS is proven to be an independent predictor of:both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3 and 3+41-3.

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report.


See sample reports

For patients with:

Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.

Start Report Guide
Start Report Guide
Start Report Guide
Start Report Guide
Start Report Guide

1. Van Den Eeden et al. AUA 2017. Abstract 17-6551.
2. Klein et al. Eur Urol. 2014.
3. Cullen et al. Eur Urol. 2014.

*Adverse pathology defined as Gleason ≥4+3 and/or pT3+.
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

One Urologist's Perspective


Ketan Badani, MD teaches and practices urology at Mount Sinai. Hear how the Oncotype DX GPS test helps him feel much more confident in treatment option discussions with patients.

Patient Video:
What to Expect


Use this video to help your patients understand why you've ordered them the Oncotype DX GPS test.

Patient Video:
Understanding Your Results


This video helps your patients prepare before coming in to discuss their results with you.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™